PirarubicinTopo II inhibitor;antineoplastic;analogue of doxorubicin CAS# 72496-41-4 |
- GSK256066 2,2,2-trifluoroacetic acid
Catalog No.:BCC1605
CAS No.:1415560-64-3
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Oglemilast
Catalog No.:BCC1817
CAS No.:778576-62-8
- AN-2728
Catalog No.:BCC1361
CAS No.:906673-24-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 72496-41-4 | SDF | Download SDF |
| PubChem ID | 3033521 | Appearance | Powder |
| Formula | C32H37NO12 | M.Wt | 627.64 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | THP | ||
| Solubility | DMSO : 50 mg/mL (79.66 mM; Need ultrasonic) | ||
| Chemical Name | (9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione | ||
| SMILES | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)OC6CCCCO6 | ||
| Standard InChIKey | KMSKQZKKOZQFFG-YHKVCKOMSA-N | ||
| Standard InChI | InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19?,21+,22-,31+,32-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Pirarubicin is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.In Vitro:Pirarubicin is a topoisomerase II inhibitor[1]. Pirarubicin shows inhibitory activities against M5076 and Ehrlich cells, with IC50s of 0.366 and 0.078 μM, respectively. The cytotoxicity of Pirarubicin toward M5076 cells is lower than toward Ehrlich cells, and this is due to the much lower expression of topoisomerase II in M5076 cells than in Ehrlich cells[2]. Pirarubicin (2.5, 5, 10 μg/mL) significantly induces autophagy in a dose dependent manner in bladder cancer (T24, EJ, 5637, J82 and UM-UC-3) cells. Furthmore, Pirarubicin (5 μg/mL) induces apoptosis through inhibition of mTOR/p70S6K/4E-BP1 in bladder cancer cells, and this effect is enhanced by inhibition of autophagy[3].In Vivo:Pirarubicin (18 mg/kg, i.v.) significantly elevates serum level of BNP, CK-MB, CTnT, LDH, and MDA compared with those in the control group in acute cardiac toxicity rats. Pirarubicin also lowers heart rate, and depresses R-wave voltage, and prolongation of QT intervals in the acute cardiac toxicity model[4]. References: | |||||
Pirarubicin Dilution Calculator
Pirarubicin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5933 mL | 7.9664 mL | 15.9327 mL | 31.8654 mL | 39.8318 mL |
| 5 mM | 0.3187 mL | 1.5933 mL | 3.1865 mL | 6.3731 mL | 7.9664 mL |
| 10 mM | 0.1593 mL | 0.7966 mL | 1.5933 mL | 3.1865 mL | 3.9832 mL |
| 50 mM | 0.0319 mL | 0.1593 mL | 0.3187 mL | 0.6373 mL | 0.7966 mL |
| 100 mM | 0.0159 mL | 0.0797 mL | 0.1593 mL | 0.3187 mL | 0.3983 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin. Intercalates into DNA and interacts with Topo II (topoisomerase II) and supressing DNA replication. Pirarubicin is an inhibitor of Topo II.
- STF 31
Catalog No.:BCC7938
CAS No.:724741-75-7
- Psora 4
Catalog No.:BCC7927
CAS No.:724709-68-6
- Praeruptorin C
Catalog No.:BCN4991
CAS No.:72463-77-5
- 11-Hydroxytephrosin
Catalog No.:BCN4861
CAS No.:72458-85-6
- Aniracetam
Catalog No.:BCC4219
CAS No.:72432-10-1
- Miglitol
Catalog No.:BCC4921
CAS No.:72432-03-2
- Acifran
Catalog No.:BCC7170
CAS No.:72420-38-3
- Aflatoxin G2
Catalog No.:BCC9215
CAS No.:7241-98-7
- Meglumine Metrizoate
Catalog No.:BCC5631
CAS No.:7241-11-4
- 6-Methoxydihydrosanguinarine
Catalog No.:BCN7581
CAS No.:72401-54-8
- X-Gal
Catalog No.:BCC1211
CAS No.:7240-90-6
- Oxacillin sodium monohydrate
Catalog No.:BCC4816
CAS No.:7240-38-2
- Methyl vanillate glucoside
Catalog No.:BCN4033
CAS No.:72500-11-9
- Felodipine
Catalog No.:BCC4402
CAS No.:72509-76-3
- Lycobetaine
Catalog No.:BCN8313
CAS No.:72510-04-4
- Specioside
Catalog No.:BCN4280
CAS No.:72514-90-0
- Paeonolide
Catalog No.:BCN2805
CAS No.:72520-92-4
- XCT790
Catalog No.:BCC5121
CAS No.:725247-18-7
- Polygonal
Catalog No.:BCN4281
CAS No.:72537-20-3
- 6-chloro-9h-fluoren-2-amine
Catalog No.:BCC9231
CAS No.:7254-05-9
- GIP (1-39)
Catalog No.:BCC5890
CAS No.:725474-97-5
- Ceftazidime
Catalog No.:BCC5274
CAS No.:72558-82-8
- Rifabutin
Catalog No.:BCC4936
CAS No.:72559-06-9
- Angeloylgomisin Q
Catalog No.:BCN7033
CAS No.:72561-28-5
Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.[Pubmed:27934482]
Mol Pharm. 2016 Dec 5;13(12):4106-4115.
Many conjugates of water-soluble polymers with biologically active molecules were developed during the last two decades. Although, therapeutic effects of these conjugates are affected by the properties of carriers, the properties of the attached drugs appear more important than the same carrier polymer in this case. Pirarubicin (THP), a tetrahydropyranyl derivative of doxorubicin (DOX), demonstrated more rapid cellular internalization and potent cytotoxicity than DOX. Here, we conjugated the THP or DOX to N-(2-hydroxypropyl)methacrylamide copolymer via a hydrazone bond. The polymeric prodrug conjugates, P-THP and P-DOX, respectively, had comparable hydrodynamic sizes and drug loading. Compared with P-DOX, P-THP showed approximately 10 times greater cellular uptake during a 240 min incubation and a cytotoxicity that was more than 10 times higher during a 72-h incubation. A marginal difference was seen in P-THP and P-DOX accumulation in the liver and kidney at 6 h after drug administration, but no significant difference occurred in the tumor drug concentration during 6-24 h after drug administration. Antitumor activity against xenograft human pancreatic tumor (SUIT2) in mice was greater for P-THP than for P-DOX. To sum up, the present study compared the biological behavior of two different drugs, each attached to an N-(2-hydroxypropyl)methacrylamide copolymer carrier, with regard to their uptake by tumor cells, body distribution, accumulation in tumors, cytotoxicity, and antitumor activity in vitro and in vivo. No differences in the tumor cell uptake of the polymer-drug conjugates, P-THP and P-DOX, were observed. In contrast, the intracellular uptake of free THP liberated from the P-THP was 25-30 times higher than that of DOX liberated from P-DOX. This finding indicates that proper selection of the carrier, and especially conjugated active pharmaceutical ingredient (API) are most critical for anticancer activity of the polymer-drug conjugates. THP, in this respect, was found to be a more preferable API for polymer conjugation than DOX. Hence the treatment based on enhanced permeability and retention (EPR) effect that targets more selectively to solid tumors can be best achieved with THP, although both polymer conjugates of DOX and THP exhibited the EPR effects and drug release profiles in acidic pH similarly.
Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.[Pubmed:27936775]
Mol Pharm. 2017 Jan 3;14(1):296-309.
Chemotherapeutic agents trigger antitumor immune response through inducing immunogenic tumor cell death. However, severe toxicity to immune system and insufficient immunogenic cell death hinder chemotherapy from arousing efficient antitumor immunity in vivo. In this study, the cytotoxic drug, Pirarubicin (THP), was entrapped into nanostructured lipid carriers (NLC); THP-NLC significantly reduced the toxicity of THP to immune system and improved immune status of breast cancer bearing mice. When THP-NLC was coinjected with iRGD (a tumor-penetrating peptide), drug accumulation in tumors was greatly elevated, which led to significant control of tumor growth and increase of immunogenic tumor cell death. Subsequently, the cytotoxic T lymphocytes (CD3(+) and CD8(+) cells) infiltration and cytokine (IFN-gamma and INF-alpha) secretion in tumors were heavily increased. The efficient T-cell dependent control of tumors in the late stage and the lower side effects contributed to the longest whole survival of THP-NLC + iRGD treated mice. Therefore, the coadministration of THP-NLC with iRGD resulted in increased tumor cell direct-killing death and enhanced antitumor immune response. Our results illustrated that THP could serve as an immunogenic cell death inducer and the proposed drug delivery strategy might impact cancer immunotherapy by arousing increased immunogenic tumor cell death.
Rutin Protects against Pirarubicin-Induced Cardiotoxicity through TGF-beta1-p38 MAPK Signaling Pathway.[Pubmed:28367221]
Evid Based Complement Alternat Med. 2017;2017:1759385.
We investigated the potential protective effect of rutinum (RUT) against Pirarubicin- (THP-) induced cardiotoxicity. THP was used to induce toxicity in rat H9c2 cardiomyoblasts. Positive control cells were pretreated with a cardioprotective agent dexrazoxane (DZR) prior to treatment with THP. Some of the cells were preincubated with RUT and a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, both individually and in combination, prior to THP exposure. At a dose range of 30-70 muM, RUT significantly prevented THP-induced reduction in cell viability; the best cardioprotective effect was observed at a dose of 50 muM. Administration of RUT and SB203580, both individually as well as in combination, suppressed the elevation of intracellular ROS, inhibited cell apoptosis, and reversed the THP-induced upregulation of TGF-beta1, p-p38 MAPK, cleaved Caspase-9, Caspase-7, and Caspase-3. A synergistic effect was observed on coadministration of RUT and SB203580. RUT protected against THP-induced cardiotoxicity by inhibition of ROS generation and suppression of cell apoptosis. The cardioprotective effect of RUT appears to be associated with the modulation of the TGF-beta1-p38 MAPK signaling pathway.
Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.[Pubmed:27858183]
Int J Clin Oncol. 2017 Apr;22(2):387-396.
BACKGROUND: Anthracyclines are used to treat childhood acute lymphoblastic leukemia (ALL). Even when administered at low doses, these agents are reported to cause progressive cardiac dysfunction. We conducted a clinical trial comparing the toxicities of two anthracyclines, Pirarubicin (THP) and daunorubicin (DNR), in the treatment of childhood ALL. The results from our study that relate to acute and late toxicities are reported here. METHODS: 276 children with B-ALL were enrolled in the trial from April 1997 to March 2002 and were randomly assigned to receive a regimen including either THP (25 mg/m(2) x 11) or DNR (30 mg/m(2) x 11). Acute toxicity was prospectively assessed based on the National Cancer Institute Common Toxicity Criteria. Acute hematological toxicity was also examined via some parameters. Patients with event-free survival of >5 years were retrospectively surveyed for cardiac function at 5 and 10 years and at the most recent assessment more than 10 years from the onset of ALL. RESULTS: Acute hematological toxicity in the early phase was more significant in the THP arm. Based on ultrasound cardiography, cardiac function was impaired in both groups during the follow-up period, but there was no significant difference between the groups except for a greater decline in fractional shortening on ultrasound cardiography in the DNR arm. CONCLUSIONS: While acute hematological toxicity was more significant in the THP arm, THP also appeared to be less cardiotoxic. However, the evaluation of late cardiotoxicity was limited because only a few subjects were followed beyond 10 years after ALL onset. Considering that the THP regimen produced an EFS rate comparable with that of the DNR regimen, the efficacy and toxicity of THP at reduced doses should be studied in order to identify potentially safer regimens.
